What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at third-quarter-end, with a position valued at approximately $634 million. ARK decreased its exposure slightly in Q3, reducing its holdings from 10.18 million to 9.79 million shares. As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equival ...